Orange Maurice, Reuter Uwe, Hobohm Uwe
Klinik Arlesheim, Switzerland.
Klinik-im-LEBEN, Greiz, Germany.
Integr Cancer Ther. 2016 Dec;15(4):502-511. doi: 10.1177/1534735416649916. Epub 2016 May 20.
The following four observations point in the same direction, namely that there is an unleveraged potential for stimulating the innate immune system against cancer: (1) experimental treatments with bacterial extracts more than 100 years ago by Coley and contemporaries, (2) a positive correlation between spontaneous regressions and febrile infection, (3) epidemiological data suggesting an inverse correlation between a history of infection and the likelihood of developing cancer, and (4) our recent finding that a cocktail of pattern recognition receptor ligands (PRRLs) can eradicate solid tumors in cancer mice if applied metronomically. Because the main immunostimulating component of mistletoe extract (ME), mistletoe lectin, has been shown to be a PRRL as well, we suggest to apply ME in combination with additional PRRLs. Additional PRRLs can be found in approved drugs already on the market. Therefore, augmentation of ME might be feasible, with the aim of reattaining the old successes using approved drugs rather than bacterial extracts.
以下四点观察结果都指向同一个方向,即存在刺激先天免疫系统对抗癌症的未被利用的潜力:(1)100多年前科利及其同时代人用细菌提取物进行的实验性治疗;(2)自发消退与发热性感染之间的正相关;(3)流行病学数据表明感染史与患癌可能性之间呈负相关;(4)我们最近的发现,即模式识别受体配体(PRRL)鸡尾酒疗法若以节律性方式应用,可根除癌症小鼠体内的实体瘤。由于已证明槲寄生提取物(ME)的主要免疫刺激成分槲寄生凝集素也是一种PRRL,我们建议将ME与其他PRRL联合应用。其他PRRL可在已上市的获批药物中找到。因此,增强ME的效果可能是可行的,目的是利用获批药物而非细菌提取物重现过去的成功。